Pasireotide (Signifor®)

Assessment Status Rapid Review Complete
Drug Pasireotide
Brand Signifor®
Indication For the treatment of adult patients with Cushing’s Disease for whom surgery is not an option or for whom surgery has failed
Assessment Process
Rapid review commissioned 29/03/2012
Rapid review completed 10/04/2012
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.